 |
BioWorld-International-2011-03-02
Study Reveals Genetic Basis for Self-Healing Skin Tumor
BLA for Pharming's, Santarus' HAE Drug Refused by FDA
LONDON – The FDA issued a refusal to file notice to Pharming NV and its partner Santarus Inc., for Rhucin, a recombinant protein product for treating hereditary angioedema (HAE), which is generated in the milk of transgenic rabbits. (BioWorld International)